| Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology JL Mohler, ES Antonarakis, AJ Armstrong, AV D’Amico, BJ Davis, T Dorff, ... Journal of the National Comprehensive Cancer Network 17 (5), 479-505, 2019 | 1345 | 2019 |
| Genomic hallmarks and structural variation in metastatic prostate cancer DA Quigley, HX Dang, SG Zhao, P Lloyd, R Aggarwal, JJ Alumkal, A Foye, ... Cell 174 (3), 758-769. e9, 2018 | 734 | 2018 |
| International Spine Radiosurgery Consortium consensus guidelines for target volume definition in spinal stereotactic radiosurgery BW Cox, DE Spratt, M Lovelock, MH Bilsky, E Lis, S Ryu, J Sheehan, ... International Journal of Radiation Oncology* Biology* Physics 83 (5), e597-e605, 2012 | 578 | 2012 |
| Androgen receptor signaling regulates DNA repair in prostate cancers WR Polkinghorn, JS Parker, MX Lee, EM Kass, DE Spratt, PJ Iaquinta, ... Cancer discovery 3 (11), 1245-1253, 2013 | 576 | 2013 |
| A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy ZS Zumsteg, DE Spratt, I Pei, Z Zhang, Y Yamada, M Kollmeier, ... European urology 64 (6), 895-902, 2013 | 423 | 2013 |
| Association of black race with prostate cancer–specific and other-cause mortality RT Dess, HE Hartman, BA Mahal, PD Soni, WC Jackson, MR Cooperberg, ... JAMA oncology 5 (7), 975-983, 2019 | 419 | 2019 |
| NCCN guidelines insights: Prostate cancer, version 1.2021: Featured updates to the NCCN guidelines E Schaeffer, S Srinivas, ES Antonarakis, AJ Armstrong, JE Bekelman, ... Journal of the National Comprehensive Cancer Network 19 (2), 134-143, 2021 | 384 | 2021 |
| PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer A Bosch, Z Li, A Bergamaschi, H Ellis, E Toska, A Prat, JJ Tao, DE Spratt, ... Science translational medicine 7 (283), 283ra51-283ra51, 2015 | 365 | 2015 |
| Racial/ethnic disparities in genomic sequencing DE Spratt, T Chan, L Waldron, C Speers, FY Feng, OO Ogunwobi, ... JAMA oncology 2 (8), 1070-1074, 2016 | 333 | 2016 |
| Stereotactic body radiation therapy for localized prostate cancer: a systematic review and meta-analysis of over 6,000 patients treated on prospective studies WC Jackson, J Silva, HE Hartman, RT Dess, AU Kishan, WH Beeler, ... International Journal of Radiation Oncology* Biology* Physics 104 (4), 778-789, 2019 | 331 | 2019 |
| Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with Gleason score 9 … AU Kishan, RR Cook, JP Ciezki, AE Ross, MM Pomerantz, PL Nguyen, ... Jama 319 (9), 896-905, 2018 | 329 | 2018 |
| Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study MJ Morris, SP Rowe, MA Gorin, L Saperstein, F Pouliot, D Josephson, ... Clinical Cancer Research 27 (13), 3674-3682, 2021 | 316 | 2021 |
| An integrated multidisciplinary algorithm for the management of spinal metastases: an International Spine Oncology Consortium report DE Spratt, WH Beeler, FY de Moraes, LD Rhines, JJ Gemmete, ... The Lancet Oncology 18 (12), e720-e730, 2017 | 312 | 2017 |
| Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer DE Spratt, X Pei, J Yamada, MA Kollmeier, B Cox, MJ Zelefsky International Journal of Radiation Oncology* Biology* Physics 85 (3), 686-692, 2013 | 310 | 2013 |
| Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis R Morrison, SM Schleicher, Y Sun, KJ Niermann, S Kim, DE Spratt, ... Journal of oncology 2011 (1), 941876, 2011 | 307 | 2011 |
| Associations of luminal and basal subtyping of prostate cancer with prognosis and response to androgen deprivation therapy SG Zhao, SL Chang, N Erho, M Yu, J Lehrer, M Alshalalfa, C Speers, ... JAMA oncology 3 (12), 1663-1672, 2017 | 289 | 2017 |
| The DNA methylation landscape of advanced prostate cancer SG Zhao, WS Chen, H Li, A Foye, M Zhang, M Sjöström, R Aggarwal, ... Nature genetics 52 (8), 778-789, 2020 | 285 | 2020 |
| Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer AU Kishan, A Dang, AJ Katz, CA Mantz, SP Collins, N Aghdam, FI Chu, ... JAMA network open 2 (2), e188006-e188006, 2019 | 283 | 2019 |
| Use of active surveillance or watchful waiting for low-risk prostate cancer and management trends across risk groups in the United States, 2010-2015 BA Mahal, S Butler, I Franco, DE Spratt, TR Rebbeck, AV D’Amico, ... Jama 321 (7), 704-706, 2019 | 238 | 2019 |
| A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER) LF Valle, EJ Lehrer, D Markovic, D Elashoff, R Levin-Epstein, RJ Karnes, ... European urology 80 (3), 280-292, 2021 | 237 | 2021 |
Felix FengProfessor of Radiation Oncology, Urology, and Medicine, University of California at San FranciscoVerified email at ucsf.edu
